Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002538019 | SCV000939027 | likely benign | Dyskeratosis congenita, autosomal dominant 2; Idiopathic Pulmonary Fibrosis | 2024-07-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004559667 | SCV002653891 | uncertain significance | Dyskeratosis congenita | 2022-03-03 | criteria provided, single submitter | clinical testing | The p.H189Q variant (also known as c.567C>A), located in coding exon 2 of the TERT gene, results from a C to A substitution at nucleotide position 567. The histidine at codon 189 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Gene |
RCV003332255 | SCV004040436 | uncertain significance | not provided | 2023-03-28 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Observed in an individual with breast cancer (Li et al., 2018); This variant is associated with the following publications: (PMID: 27149842, 29316957) |
Fulgent Genetics, |
RCV005047074 | SCV005669173 | uncertain significance | Acute myeloid leukemia; Dyskeratosis congenita, autosomal dominant 2; Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 1; Melanoma, cutaneous malignant, susceptibility to, 9 | 2024-02-21 | criteria provided, single submitter | clinical testing |